Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
- PMID: 1683908
- DOI: 10.1093/jnci/83.24.1797-a
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
Abstract
Taxol, an antimicrotubule agent, has shown promise for efficacy in treatment of breast cancer, but severe hypersensitivity reactions led to cessation of many phase I clinical trials. Consequently, investigators and the National Cancer Institute recommended that phase I and II studies of this agent use 24-hour infusions and antiallergic medications. Using a premedication regimen effective in preventing hypersensitivity reactions, we have performed a phase II trial of taxol in patients with metastatic breast cancer. Taxol was administered to 25 patients at a dose of 250 mg/m2 by 24-hour infusion every 21 days. These patients had received only one prior chemotherapy regimen, either adjuvant to surgery or for metastatic disease; all but two had received doxorubicin. In 60% of the patients, the dominant site of disease was the viscera. All patients were assessable. In April 1991, at a median time on study of 9 months (range, 5-13+ months), the objective response rate was 56% (12% complete and 44% partial; 95% confidence interval, 35%-76%). Disease progressed in only 8% of the patients. The median number of courses of therapy was 11. Granulocytopenia was the dose-limiting toxic effect, but neutropenia with fever occurred in only 5% of 232 courses. A chronic glove-and-stocking neuropathy developed in most patients, but no allergic reactions occurred. We conclude that taxol is an active agent in the treatment of metastatic breast cancer and that it warrants continued study. Currently, we are conducting a phase I trial of taxol plus doxorubicin. Future trials should address the optimal effective dose, the optimal sequencing of combinations, mechanisms of drug resistance in tumors, and dose-limiting toxic effects (particularly cardiac toxic effects of taxol given as a single agent or in drug combinations).
Similar articles
-
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22. Semin Oncol. 1996. PMID: 8893894 Clinical Trial.
-
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.Ann Oncol. 1999 Apr;10(4):403-11. doi: 10.1023/a:1008360406322. Ann Oncol. 1999. PMID: 10370782 Clinical Trial.
-
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75. doi: 10.1093/jnci/87.15.1169. J Natl Cancer Inst. 1995. PMID: 7674322 Clinical Trial.
-
Treatment of metastatic breast cancer with paclitaxel and doxorubicin.Semin Oncol. 1995 Dec;22(6 Suppl 15):13-7. Semin Oncol. 1995. PMID: 8643964 Review.
-
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.Oncology (Williston Park). 1997 Apr;11(4 Suppl 3):19-23. Oncology (Williston Park). 1997. PMID: 9144686 Review.
Cited by
-
Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas.J Clin Med. 2021 Apr 23;10(9):1846. doi: 10.3390/jcm10091846. J Clin Med. 2021. PMID: 33922821 Free PMC article.
-
Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges.ISRN Pharmacol. 2012;2012:623139. doi: 10.5402/2012/623139. Epub 2012 Aug 12. ISRN Pharmacol. 2012. PMID: 22934190 Free PMC article.
-
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).Br J Cancer. 2001 Jul 20;85(2):141-6. doi: 10.1054/bjoc.2001.1897. Br J Cancer. 2001. PMID: 11461067 Free PMC article. Clinical Trial.
-
Drug-Triggered Self-Assembly of Linear Polymer into Nanoparticles for Simultaneous Delivery of Hydrophobic and Hydrophilic Drugs in Breast Cancer Cells.ACS Omega. 2017 Dec 31;2(12):8730-8740. doi: 10.1021/acsomega.7b01400. Epub 2017 Dec 7. ACS Omega. 2017. PMID: 30023590 Free PMC article.
-
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.Am J Pathol. 2002 Nov;161(5):1917-24. doi: 10.1016/S0002-9440(10)64467-7. Am J Pathol. 2002. PMID: 12414537 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous